Troy Lister

1.5k total citations
35 papers, 1.1k citations indexed

About

Troy Lister is a scholar working on Organic Chemistry, Pharmacology and Molecular Medicine. According to data from OpenAlex, Troy Lister has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Organic Chemistry, 14 papers in Pharmacology and 13 papers in Molecular Medicine. Recurrent topics in Troy Lister's work include Antibiotic Resistance in Bacteria (13 papers), Synthetic Organic Chemistry Methods (8 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Troy Lister is often cited by papers focused on Antibiotic Resistance in Bacteria (13 papers), Synthetic Organic Chemistry Methods (8 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Troy Lister collaborates with scholars based in United States, Australia and Sweden. Troy Lister's co-authors include Tricia L. May‐Dracka, Dean G. Brown, Ross M. Denton, Michael V. Perkins, Ana Montero, David J. Edmonds, Michael J. Pucci, Thomas Parr, T. P. Zabawa and K. C. Nicolaou and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Circulation.

In The Last Decade

Troy Lister

35 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Troy Lister United States 17 407 393 369 355 174 35 1.1k
Xinxin Hu China 20 223 0.5× 278 0.7× 464 1.3× 404 1.1× 105 0.6× 76 1.1k
Christopher T. Lohans Canada 26 178 0.4× 430 1.1× 880 2.4× 399 1.1× 224 1.3× 53 1.6k
Gianfranco De Pascale Canada 13 167 0.4× 509 1.3× 483 1.3× 308 0.9× 98 0.6× 20 1.1k
Bryon Drown United States 11 190 0.5× 333 0.8× 516 1.4× 186 0.5× 128 0.7× 17 1.1k
Sandrine Alibert France 17 249 0.6× 406 1.0× 493 1.3× 202 0.6× 82 0.5× 30 1.2k
Linda Ejim Canada 17 168 0.4× 470 1.2× 627 1.7× 295 0.8× 144 0.8× 19 1.4k
Son T. Nguyen United States 13 302 0.7× 534 1.4× 419 1.1× 224 0.6× 67 0.4× 21 1.1k
Tarek S. Ibrahim Egypt 28 729 1.8× 242 0.6× 901 2.4× 187 0.5× 143 0.8× 94 1.7k
R.A. Giacobbe United States 26 393 1.0× 293 0.7× 568 1.5× 691 1.9× 68 0.4× 33 1.6k
Jin‐Hwan Kwak South Korea 18 167 0.4× 158 0.4× 438 1.2× 196 0.6× 96 0.6× 47 984

Countries citing papers authored by Troy Lister

Since Specialization
Citations

This map shows the geographic impact of Troy Lister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Troy Lister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Troy Lister more than expected).

Fields of papers citing papers by Troy Lister

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Troy Lister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Troy Lister. The network helps show where Troy Lister may publish in the future.

Co-authorship network of co-authors of Troy Lister

This figure shows the co-authorship network connecting the top 25 collaborators of Troy Lister. A scholar is included among the top collaborators of Troy Lister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Troy Lister. Troy Lister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Urnov, Fyodor D., Sadik H. Kassim, Kiran Musunuru, et al.. (2025). Advancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Danaher. Cytotherapy. 27(10). 1151–1163. 2 indexed citations
2.
Rohde, Ellen, Richard Lee, Anne Marie Mazzola, et al.. (2025). † VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies. Journal of clinical lipidology. 19(3). e68–e68. 1 indexed citations
3.
Kassim, Sadik H., Fyodor D. Urnov, Kiran Musunuru, et al.. (2025). Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable. Nature Biotechnology. 43(7). 1047–1049. 2 indexed citations
4.
Alamneh, Yonas A., Vlado Antonic, Michael J. Pucci, et al.. (2022). Minocycline and the SPR741 Adjuvant Are an Efficacious Antibacterial Combination for Acinetobacter baumannii Infections. Antibiotics. 11(9). 1251–1251. 8 indexed citations
5.
Pidot, Sacha J., Jessica L. Porter, Troy Lister, & Timothy P. Stinear. (2021). In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS neglected tropical diseases. 15(7). e0009636–e0009636. 12 indexed citations
6.
Mendes, Rodrigo E., Paul R. Rhomberg, Troy Lister, et al.. (2019). Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Microbial Drug Resistance. 26(4). 319–328. 10 indexed citations
7.
8.
9.
Zabawa, T. P., Michael J. Pucci, Thomas Parr, & Troy Lister. (2016). Treatment of Gram-negative bacterial infections by potentiation of antibiotics. Current Opinion in Microbiology. 33. 7–12. 86 indexed citations
10.
Kawatkar, Sameer, Moriah M. Gagnon, Choi-Lai Tiong-Yip, et al.. (2016). Design and structure–activity relationships of novel inhibitors of human rhinovirus 3C protease. Bioorganic & Medicinal Chemistry Letters. 26(14). 3248–3252. 14 indexed citations
11.
Cumming, John G., M. Raymond V. Finlay, Fabrizio Giordanetto, et al.. (2014). Potential Strategies for Increasing Drug-Discovery Productivity. Future Medicinal Chemistry. 6(5). 515–527. 16 indexed citations
12.
Brown, Dean G., Troy Lister, & Tricia L. May‐Dracka. (2013). New natural products as new leads for antibacterial drug discovery. Bioorganic & Medicinal Chemistry Letters. 24(2). 413–418. 156 indexed citations
13.
Nicolaou, K. C., Troy Lister, Ross M. Denton, & Christine F. Gelin. (2008). Total synthesis of artochamins F, H, I, and J through cascade reactions. Tetrahedron. 64(21). 4736–4757. 22 indexed citations
14.
Nicolaou, K. C., Antonia F. Stepan, Troy Lister, et al.. (2008). Design, Synthesis, and Biological Evaluation of Platensimycin Analogues with Varying Degrees of Molecular Complexity. Journal of the American Chemical Society. 130(39). 13110–13119. 94 indexed citations
15.
Nicolaou, K. C., Troy Lister, Ross M. Denton, & Christine F. Gelin. (2007). Cascade Reactions Involving Formal [2+2] Thermal Cycloadditions: Total Synthesis of Artochamins F, H, I, and J. Angewandte Chemie International Edition. 46(39). 7501–7505. 34 indexed citations
16.
Nicolaou, K. C., Troy Lister, Ross M. Denton, Ana Montero, & David J. Edmonds. (2007). Adamantaplatensimycin: A Bioactive Analogue of Platensimycin. Angewandte Chemie International Edition. 46(25). 4712–4714. 99 indexed citations
17.
Lister, Troy & Michael V. Perkins. (2006). Total Synthesis of Auripyrone A. Angewandte Chemie International Edition. 45(16). 2560–2564. 29 indexed citations
18.
Lister, Troy & Michael V. Perkins. (2006). Total Synthesis of Auripyrone A. Angewandte Chemie. 118(16). 2622–2626. 7 indexed citations
19.
Lister, Troy & Michael V. Perkins. (2004). Total Synthesis of a Hemiacetal Polypropionate from Siphonaria australis. Australian Journal of Chemistry. 57(8). 787–797. 11 indexed citations
20.
Jeffery, David W., Troy Lister, & Rolf H. Prager. (2004). The Role of Hydrogen Bonding in the Intramolecular Cyclization of Carbenes. Australian Journal of Chemistry. 57(5). 491–496. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinxin Hu Breakdown of academic impact, for papers by Christopher T. Lohans Breakdown of academic impact, for papers by Gianfranco De Pascale Breakdown of academic impact, for papers by Bryon Drown Breakdown of academic impact, for papers by Sandrine Alibert Breakdown of academic impact, for papers by Linda Ejim Breakdown of academic impact, for papers by Son T. Nguyen Breakdown of academic impact, for papers by Tarek S. Ibrahim Breakdown of academic impact, for papers by R.A. Giacobbe Breakdown of academic impact, for papers by Jin‐Hwan Kwak
Rankless by CCL
2026